Adam C. Palmer, PhD, on Immune Checkpoint Inhibitors: Additive to or Synergistic With Other Treatments?
AACR Virtual Annual Meeting 2020 II
Adam C. Palmer, PhD, of the University of North Carolina at Chapel Hill, discusses combining immune checkpoint inhibitors with other cancer therapies to provide patients with more chances of a response. In principle, similar benefits may result from sequential or biomarker-stratified treatments, which could be valuable in cases where toxicities may prevent full-dose combinations (Abstract 1047).
The ASCO Post Staff
Xavier Llor, MD, PhD, of Yale University School of Medicine, discusses the steep rise of early-onset colorectal cancer over the past 15 years, which cannot be explained by genetic predisposition but may be prompted by environmental factors (Session ED35).
The ASCO Post Staff
Alfonso Bencomo Álvarez, PhD, of Texas Tech University Health Sciences Center, discusses his retrospective study of the incidence and survival for patients with hematologic malignancies residing at the United States/Mexico border. The analysis showed that 10-year survival rates for Hispanic patients with ALL, AML, and CML were significantly lower for those who lived in El Paso than for those who lived elsewhere in Texas (Abstract 4343).
The ASCO Post Staff
Stacey A. Fedewa, PhD, of the American Cancer Society, discusses the increasing incidence rates of colorectal, breast, kidney, thyroid, uterine corpus, and cervical disease in younger patients. Data show that colorectal cancer is increasing most rapidly, while breast cancer—the most common cancer among young women—is rising at a slower pace (Session ED35).
The ASCO Post Staff
Robert A. Winn, MD, of Virginia Commonwealth University and the Massey Cancer Center, discusses the COVID-19 pandemic and how it is exacerbating disparities in cancer care among racial and ethnic minorities and the medically underserved who are disproportionately affected by the coronavirus (Session VSS06).
The ASCO Post Staff
Ralph R. Weichselbaum, MD, of the University of Chicago Cancer Research Center, explores the question of whether radiotherapy is the principal curative treatment with immunotherapy or activates immunotherapy. He also discussed how to improve the interaction of these treatments, perhaps with vaccination, transfer of genetically engineered T cells, or checkpoint inhibitors (Session ED37).
